Skovgaard R, Jon Ploug U, Clinical Therapeutics 2015; 37(8): 1677-88., . Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada.
Muduma G, Odeyemi I, Journal of Medical Economics 2015; 18(12): 1050-9.. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
Muratalina A, Value in Health Regional Issues 2015; 7: 74-9., Nurbekova A, Abduakhassova G, Zhubandykova L, Roze S, Karamalis M, Shamshatova G, Demessinov A, Dunne D’Agostino N, Lynch P, Larisa Yedigarova L, Klots M, , Welsh J, Kaufman F. Project Baiterek: a patient access program to improve clinical outcomes and quality of life in children with type 1 diabetes in Kazakhstan.
Roze S, Diabetic Medicine 2015; 32(11): 1415-24., , de Portu S, Nørgaard K, Pickup JC. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: a systematic review.
Expert Review of Endocrinology & Metabolism 2015; 10: 243–57., Boye KS, Perez-Nieves M, , Bae JP. Cardiovascular risk profiles in Type 2 diabetes and the impact of geographical setting.
Goh SY, Tan SC, Lim LC, Chua B, Journal of Diabetology 2015; 1:2.. Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore.
Value in Health Regional Issues 2015; 8c: 20-7., Aguilar Garza JL, Enríquez Vázquez CJ, Jain P, . Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico.
Diabetes Research and Clinical Practice 2015; 109(1): 95-103., Curtis BH, , Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
Roze S, Diabetic Medicine 2015; 32(5): 618-26., Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes.
Expert Opinion on Drug Delivery 2015; 12(3): 353-60., Kappelgaard AM, Seitz L. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices.
Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Diabetes Therapy 2015; 6(1): 61-74., . Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.
Bargalló-Rocha JE, Lara-Medina F, Pérez-Sánchez V, Vázquez-Romo R, Villarreal-Garza C, Martínez-Said H, Shaw-Dulin RJ, Mohar-Betancourt A, Advances in Therapy 2015; 32(3): 239-53., Plun-Favreau J, . Cost-effectiveness of the 21-gene breast cancer assay in Mexico.
BMC Infectious Diseases 2015; 15(1): 19., Cerri K, . Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.